替格瑞洛与氯吡格雷在择期经皮冠状动脉介入治疗中的比较(ALPHEUS):一项随机、开放标签、3b期试验
ALPHEUS为在法国和捷克49家医院进行的3b期随机开放标签试验,纳入1910例有至少一项高危特征的稳定冠心病行择期PCI患者,1:1随机接受替格瑞洛(180 mg负荷,90 mg每日两次,共30天)或氯吡格雷(300-600 mg负荷,75 mg每日一次,共30天)。主要安全终点大出血无差异,但30天小出血替格瑞洛组更常见(11% vs 8%;结论支持氯吡格雷作为择期PCI的标准治疗。
要点
- 两组主要安全终点大出血无差异(原文未给出具体数值)。
- 基于该结果,择期PCI的稳定冠心病患者支持使用氯吡格雷作为标准抗血小板治疗。
适用人群与场景
- 稳定冠心病且有PCI指征并至少一项高危特征的患者,在法国和捷克49家医院行择期PCI。
诊断标准与关键阈值
- 主要终点为PCI相关4型(a或b)心肌梗死或重大心肌损伤的复合终点,于PCI后48小时内(或更早出院时)评估。
- 主要安全终点为主要出血,于PCI后48小时内(或更早出院时)评估。
处置流程与药物剂量
- 替格瑞洛组:180 mg负荷剂量,此后90 mg每日两次,共30天。
- 氯吡格雷组:300-600 mg负荷剂量,此后75 mg每日一次,共30天。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 3b期随机开放标签试验,49家医院,1910例随机(替格瑞洛956例,氯吡格雷954例),意向性治疗分析排除替格瑞洛组15例、氯吡格雷组12例。
- 主要安全终点大出血两组无差异(原文未给出具体数值)。
证据类型、等级与局限
- 随机、开放标签、3b期试验;原文未给出证据等级或推荐强度。
- 局限:开放标签设计;原文未提及其他局限。
对床旁实践的改变
- 择期PCI的稳定冠心病患者中,替格瑞洛不优于氯吡格雷减少围术期心肌坏死,且增加30天小出血,支持氯吡格雷作为标准治疗。
- 原文未提及适用与不适用人群的进一步限定。
指南或共识出处
- ALPHEUS trial, ClinicalTrials.gov NCT02617290;资助:ACTION Study Group and AstraZeneca。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Percutaneous coronary intervention (PCI)-related myonecrosis is frequent and can affect the long-term prognosis of patients. To our knowledge, ticagrelor has not been evaluated in elective PCI and could reduce periprocedural ischaemic complications compared with clopidogrel, the currently recommended treatment. The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI.
METHODS: The ALPHEUS study, a phase 3b, randomised, open-label trial, was done at 49 hospitals in France and Czech Republic. Patients with stable coronary artery disease were eligible for the study if they had an indication for PCI and at least one high-risk characteristic. Eligible patients were randomly assigned (1:1) to either ticagrelor (180 mg loading dose, 90 mg twice daily thereafter for 30 days) or clopidogrel (300-600 mg loading dose, 75 mg daily thereafter for 30 days) by use of an interactive web response system, and stratified by centre. The primary outcome was a composite of PCI-related type 4 (a or b) myocardial infarction or major myocardial injury and the primary safety outcome was major bleeding, both of which were evaluated within 48 h of PCI (or at hospital discharge if earlier). The primary analysis was based on all events that occurred in the intention-to-treat population. The trial was registered with ClinicalTrials.gov, NCT02617290.
FINDINGS: Between Jan 9, 2017, and May 28, 2020, 1910 patients were randomly assigned at 49 sites, 956 to the ticagrelor group and 954 to the clopidogrel group. 15 patients were excluded from the ticagrelor group and 12 from the clopidogrel group. At 48 h, the primary outcome was observed in 334 (35%) of 941 patients in the ticagrelor group and 341 (36%) of 942 patients in the clopidogrel group (odds ratio [OR] 0·97, 95% CI 0·80-1·17; p=0·75). The primary safety outcome did not differ between the two groups, but minor bleeding events were more frequently observed with ticagrelor than clopidogrel at 30 days (105 [11%] of 941 patients in the ticagrelor group vs 71 [8%] of 942 patients in the clopidogrel group; OR 1·54, 95% CI 1·12-2·11; p=0·0070).
INTERPRETATION: Ticagrelor was not superior to clopidogrel in reducing periprocedural myocardial necrosis after elective PCI and did not cause an increase in major bleeding, but did increase the rate of minor bleeding at 30 days. These results support the use of clopidogrel as the standard of care for elective PCI.
FUNDING: ACTION Study Group and AstraZeneca.
参考来源
- Silvain J, Lattuca B, Beygui F, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020. PMID: 33202219. doi:10.1016/S0140-6736(20)32236-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。